韩国早产儿视网膜病变的发病率、长期视觉结局与死亡率:全国性人群研究
该研究利用韩国国民健康保险和残疾登记数据库,覆盖2006至2014年全部新生儿并追踪至2016年,评估早产儿视网膜病变(ROP)的发病率、视觉损害率和死亡率。结果显示ROP总发病率为每1000名新生儿1.99例,极低出生体重儿中高达317.14例;10岁时视觉损害率为每100人年2.2例,极低出生体重儿中最高为4.5例;死亡率每1000人年4.8例。
要点
- ROP总发病率为每1000名新生儿1.99例,极低出生体重儿中为317.14例。
- 10岁时视觉损害率每100人年2.2例,极低出生体重儿中最高为4.5例。
- 不同治疗方式间视觉损害比例和死亡率存在差异,需进一步验证。
核心结论
- 韩国ROP发病率约为全部新生儿的1/500,极低出生体重儿中约为1/3。
- 作为首个全国性ROP长期视觉预后人群研究,报告视觉损害率高于既往其他研究。
- 不同治疗方式间视觉结局差异和相当的死亡风险需进一步验证。
研究设计与样本
- 基于韩国国民健康保险和韩国残疾登记数据库的全国性人群研究。
- 覆盖2006至2014年全部新生儿,并纳入截至2016年诊断为ROP的所有新生儿信息。
- 按出生体重类别和治疗方式评估ROP发病率、视觉损害率和死亡率。
主要发现
- ROP发病率每1000名新生儿为1.99例,极低出生体重(<1500 g)人群为317.14例,1500-2499 g人群为25.45例,≥2500 g人群为0.29例。
- 10岁时视觉损害率为每100人年2.2例,极低出生体重人群最高为每100人年4.5例。
- 治疗病例中,激光光凝或冷冻治疗者视觉损害比例为1.6%(42/2595),抗血管内皮生长因子注射者为2.9%(2/68),玻璃体切割或巩膜扣带术者为32.2%(82/255)。
- 死亡率为每1000人年4.8例,极低出生体重人群最高,但不同治疗方式间相似。
临床怎么用
- 极低出生体重儿是ROP高发人群,应加强筛查和长期视觉随访。
- 不同治疗方式视觉结局差异需进一步验证,治疗选择应个体化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the incidence, visual prognosis, and mortality in retinopathy of prematurity (ROP) in Korea. METHODS: We used the National Health Insurance and the Korean Disability Registry database, which covers the entire newborn population in 2006 to 2014 and includes information on all newborns diagnosed with ROP until 2016. Using these databases, we evaluated the incidence, rate of visual impairment (VI), and mortality in patients with ROP according to the birth weight categories and treatment modalities. RESULTS: The ROP incidence per 1000 newborns was 1.99, which broke down into 317.14 in the very low birth weight (VLBW) less than 1500 g population, 25.45 in the 1500 to 2499 g population, and 0.29 in the 2500 g or greater population. When assessed at age 10, the VI rate was 2.2 per 100 person-years, which was highest at 4.5 per 100 person-years in the VLBW population compared with the population in other birth weight categories. Among treated cases, the proportion of VI in patients undergoing laser photocoagulation or cryotherapy was 1.6% (42/2595), which was lower than the 2.9% (2/68) of patients treated with anti-vascular endothelial growth factor injection, and 32.2% (82/255) of patients undergoing vitrectomy or scleral buckling. The mortality rate was 4.8 per 1000 person-years, which was highest in the VLBW population, but similar across treatment modalities. CONCLUSIONS: The ROP incidence in Korea was approximately 1 in 500 among all newborns, and 1 in 3 in the VLBW population. As the first nationwide population-based study of long-term visual prognosis in ROP, we report the higher VI rate in ROP than previously determined in other studies. Differences in visual outcomes and comparable mortality risks between treatment modalities require further verification.
引用
- Na KH, Kim KH, Kang TU, et al. Incidence, Long-Term Visual Outcomes, and Mortality in Retinopathy of Prematurity in Korea: A Nationwide Population-Based Study. Invest Ophthalmol Vis Sci. 2020. PMID: 32761140. doi:10.1167/iovs.61.10.14
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。